FDA's Proposed Mail-Order Import Ban Could Have "Loophole" - Rep. DeGette
This article was originally published in The Tan Sheet
Executive Summary
An exemption under a proposed FDA ban on mail-order drug imports unintentionally could create a loophole through which illegal products could enter, Rep. Diana DeGette (D-Colo.) said at a Commerce/Oversight & Investigations Subcommittee hearing June 7.
You may also be interested in...
FDA Inspection Process Tops Agency Self-Reform Agenda
FDA is highlighting the inspection process as one area in need of improvement as part of regulatory reform efforts
FDA Inspection Process Tops Agency Self-Reform Agenda
FDA is highlighting the inspection process as one area in need of improvement as part of regulatory reform efforts
FDA Inspection Process Tops Agency Self-Reform Agenda
FDA is highlighting the inspection process as one area in need of improvement as part of regulatory reform efforts